HC Wainwright & Co. Maintains Neutral on Terns Pharma, Lowers Price Target to $8
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce maintains a Neutral rating on Terns Pharma (NASDAQ:TERN) and lowers the price target from $11 to $8.
August 10, 2023 | 8:48 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Neutral rating on Terns Pharma and lowered the price target from $11 to $8.
The lowering of the price target by HC Wainwright & Co. indicates a less optimistic outlook for Terns Pharma, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100